Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

References

Page 1

	Year	Citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer Alan Sandler, Robert J. Gray, Michael C. Perry, New England Journal of Medicine	2006	5.8K
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, New England Journal of Medicine	2010	5.5K
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, New England Journal of Medicine	2017	5K
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, The Lancet Oncology Open LabelMedicineCancer GrowthPathologyCancer Genomics	2009	4.1K
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou, Yi‐Long Wu, Gongyan Chen, The Lancet Oncology MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer Treatment	2011	4K
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata, Science Translational Medicine	2011	3.5K
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, New England Journal of Medicine	2019	2.7K
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Gregory A. Masters, Sarah Temin, Christopher G. Azzoli, Journal of Clinical Oncology Low Pd-l1 ExpressionCancer TherapeuticsPd-l1 ExpressionMedicineCancer Management	2015	847
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study Takashi Seto, Terufumi Kato, Makoto Nishio, The Lancet Oncology First-line TherapyOncologyPathologyEgfr MutationsCancer Treatment	2014	745

Page 1